ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation

B. Oh, F. Messner, Y. Guo, G. Brandacher

Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2022 American Transplant Congress

Abstract number: 457

Keywords: Alloantibodies, B cells, Co-stimulation

Topic: Basic & Clinical Science » Basic & Clinical Science » 20 - VCA

Session Information

Session Name: VCA

Session Type: Rapid Fire Oral Abstract

Date: Tuesday, June 7, 2022

Session Time: 3:30pm-5:00pm

 Presentation Time: 4:00pm-4:10pm

Location: Hynes Room 313

*Purpose: Sensitization in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection constitute some of the greatest risk factors for allograft rejection and long-term graft failure. Here we investigated the effect of dual targeted desensitization using costimulatory blockade and bortezomib on DSA levels and graft survival after hindlimb transplantation in the mouse.

*Methods: C57BL/6 mice were sensitized with Balb/c skin transplants. All animals rejected the graft within 2 weeks and sensitization was confirmed by flow crossmatch. Group 1 received a desensitization protocol consisting of bortezomib (0.75mg/kg i.p.) twice and CTLA4-Ig (500µg i.p.) once per week for a total of 4 weeks before orthotopic hindlimb transplantation (day 0) together with a tolerance induction protocol consisting of anti-Thy1.2 (2mg/kg i.p.) and total body irradiation (249.7cGy) on day -1 as well as cyclophosphamide (200mg/kg i.p.) on day +3. Animals in group 2 received the desensitization protocol after hindlimb transplantation and group 3 did not receive desensitization treatment whilst otherwise following the same protocol.

*Results: Four weeks after skin transplantation, all animals developed a significantly increase in DSA levels (15.5 ±7.7-fold increase; p<0.0001). Despite the four week course of combined desensitization, animals in group 1 did not display a significant reduction in DSA levels. After hindlimb transplantation and application of the tolerance protocol, DSA levels significantly dropped to baseline levels (2.2±1.8-fold increase; p<0.0001) in all groups. In the naïve setting this tolerance protocol allows for indefinite graft survival, in animals of group 3 however, median graft survival was limited to 37 days. Combined desensitization did not improve graft survival regardless if applied before (group 1) or after (group2) hind limb transplantation, contrarily it even shortened graft survival (median 15.5 and 19 days, respectively; p=0.26). In addition, allograft rejection seemed to correlate with a rebound in DSA levels in group 1 (p=0.0037) but not in groups 2 and 3.

*Conclusions: Although effective in solid organ transplantation a combined desensitization protocol with CTLA4-Ig and bortezomib failed to show reduced DSA levels and improved allograft survival in a stringent VCA model.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Oh B, Messner F, Guo Y, Brandacher G. Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/desensitization-using-costimulatory-blockade-and-bortezomib-to-prevent-dsa-formation-and-rejection-in-reconstructive-transplantation-2/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences